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ABSTRACT OF THE THESIS 
 
The Impact of Isoniazid and Pyrazinamide Mono-resistance on Mortality among Tuberculosis 
Patients in Los Angeles County, 2010-2014 
 
by 
 
Kaewalee Soontornmon 
 
Master of Science in Epidemiology 
University of California, Los Angeles, 2017 
Professor Roger Detels, Chair 
 
Background: Isoniazid and pyrazinamide mono-resistant tuberculosis (TB) may be associated with 
poor treatment outcomes, but previous studies have found conflicting results. We assessed the 
impact of isoniazid (INH) or pyrazinamide (PZA) mono-resistance on mortality during TB 
treatment in Los Angeles County.  
 
Methods: We retrospectively reviewed drug susceptibility test patterns and treatment outcomes 
among TB cases reported to the Los Angeles County Tuberculosis Control Program from 2010 to 
2014. Multiple logistic regression was used to determine the association between isoniazid or 
pyrazinamide mono-resistance and death while controlling for patient characteristics. 
iii 
Results: Of 1,927 TB patients included in the analysis, in the multiple-logistic-regression model 
adjusting for age, gender, race, foreign-born, extra pulmonary status, and history of TB, patients 
with INH or PZA mono-resistance had higher odds of death than patients with drug-susceptible 
TB [OR 1.57 (0.93, 2.64); and OR 2.43 (0.92, 6.44), respectively]. 
  
Conclusion: Patients with INH or PZA mono-resistance were more likely to die than patients with 
drug-susceptible TB. Efforts are needed to improve treatment outcomes for INH or PZA mono-
resistant TB patients.  
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CHAPTER I: INTRODUCTION 
 
Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide with 10.4 million new 
TB cases in 2015. There were 1.4 million TB deaths and 0.4 million deaths from TB/HIV 
coinfection. Despite the decrease in the number of TB deaths by 22% from 2000 to 2015, TB still 
remains one of top ten causes of death in 2015 (1). In the United States, 9,287 cases were 
provisionally reported as new TB cases in 2016 which is the lowest number of TB cases recorded 
and slightly reduced from 2015 by 2.7%. Although the incidence rates have steadily declined since 
the strengthening of nationwide TB control programs in 1993, the goal of U.S. TB elimination will 
not be achieved in the near future.  
 
On the other hand, national TB mortality rates seemed to be leveled off at 0.2 per 100,000 
population since 2003 to 2014, and the percentage of deaths of any cause among TB patients had 
remained stable around 6.1 to 6.7% from 2007 to 2013 (2). Despite effective anti-TB therapeutics 
and chemoprophylaxis, targeted TB screening programs and strong TB Control Programs 
embedded in communities around the United States, deaths with TB remain unacceptably high. In 
order to meet the post-2015 global TB target of reducing deaths by 95% by the year 2035, it is 
essential to identify all risk factors that promote TB death. (3). For this study, we will focus on the 
aspect of drug resistant pattern on TB mortality.  
 
California (CA) is ranked 3rd in TB incidence rate in U.S., with a rate of 5.4 cases per 100,000 
population and a total of  2,133 cases in 2015, compared to the national incidence rate of 3.0 cases 
per 100,000 population (2). Based on a report on TB in California in 2015, the trend of TB 
mortality was stable at 10% since 1993. (4); however, Los Angeles County (LAC) reported TB 
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mortality at 12 % from 2010-2014, reflecting a higher magnitude of TB mortality in LAC than CA 
(5, 6). Among TB cases reported to CA in 2013, there were 215 deaths out of 2,164 cases (9.9%), 
whereas LAC reported 82 deaths out of 660 cases (12.4%). This underscores the urgent need to 
reduce TB deaths in the huge and diverse metropolitan area of LAC.  
 
Drug-resistant M. tb could be a strong predictor of TB mortality. We can categorize drug resistance 
tuberculosis (DR-TB) in 2 parts: multidrug resistance (MDR) and non-MDR resistance. For MDR 
TB, M. tb organism resist both (but not limited to) isoniazid (INH) and rifampicin (RIF). Non-
MDR, other mono or poly- drug resistance without INH and RIF concurrent infection. Most of the 
literature studying the association between drug-resistance and TB mortality focuses on multidrug 
resistance (MDR) TB; however, the non-MDR resistance might be considered as a concern 
especially in the area with high burden of non-MDR resistance. 
 
There were some controversial issues about drug resistance patterns and TB mortality. For 
example, most of previous studies reported that INH mono-resistance was associated with 
unfavorable outcome (7-16). In contrast, two studies from U.S. and Denmark reveal that there was 
no significant association between INH mono-resistant TB and poor treatment outcome (17, 18). 
Therefore, Stagg and colleagues raised the issue whether non-MDR INH resistance is a cause for 
concern. There was no definite answer across the globe, the magnitude of non-MDR resistant  
problem relied on the burden of INH resistance in each country, the pattern and extent of 
resistance-conferring mutations (19). In addition, pyrazinamide (PZA) mono-resistance was 
believed to be a risk factor for poor clinical outcome. A study from Quebec revealed the worse 
treatment result of PZA mono-resistance when compared with a drug susceptible (20), but the 
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study from San Francisco reported no significant difference between these two groups. (21). The 
results from both studies could be explained by the fact that DR-TB might not increase mortality 
in TB programs that can tailor the treatment based on drug susceptibility testing (DST) results. For 
example, receiving longer TB treatment in PZA mono-resistance could influence treatment 
outcomes. 
 
Along with the previous studies, our study highlighted both drug resistant patterns (INH and PZA) 
on TB mortality in the setting such as LAC where the treatment regimen was tailored based on 
drug resistant pattern. For non-MDR INH resistance, we hypothesized that tailoring the treatment 
regimen and intensive TB management could reduce the TB mortality in non-MDR INH resistant 
cases. For non-MDR PZA resistance, we confirmed the concept of poor treatment outcome. The 
primary objective of this study was to evaluate the association of drug resistance patterns (INH, 
PZA and MDR) on TB mortality. We did not investigate other types of first-line anti-TB drug 
resistant pattern because there were too few cases for meaningful analysis (RIF and ethambutol 
(ETM) mono-resistance). To meet this objective, we conducted a retrospective cohort study to 
evaluate TB mortality during anti-TB treatment in LAC over a 5-year period. TB patients alive at 
diagnosis and who had a full record of DST and genotype data were selected for inclusion in the 
study cohort.  
 
Moreover, we examined the issues of difference in resistant conferring mutation, the requirement 
of tailored regimens for drug resistance, and the relationship between non-MDR and MDR 
resistance support the importance of non-MDR-TB. Finally, improved understanding of the risk 
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of mortality among patients with non-MDR resistance might help to guide efforts to improve 
treatment regimen and achieve the best treatment outcome. 
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Primary Research Question 
 
Do TB cases with INH mono-resistance or PZA mono-resistance have an increased mortality risk 
during the course of TB treatment when compared to TB cases with drug-susceptible group among 
TB cases reported to the Tuberculosis Control Program in Los Angeles County between 2010-
2014?  
I hypothesize that TB patients who have INH or PZA mono-resistance will have an increased risk 
of death during TB treatment, compared to patients who has drug-susceptible. 
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CHAPTER II: BACKGROUND 
 
INH is an effective drug for treating active TB disease.  It was first synthesized in 1912 in Prague, 
Czech Republic (22). Considered a prodrug, INH is stimulated by the catalase-peroxidase katG of 
M.tb. Later, by binding inhA, an enoyl-acyl, carrier protein reductase, it obstructs fatty (mycolic) 
acid synthesis, a necessary component of bacterial cell wall. INH has two roles based on the 
reproduction speed of bacteria, INH is bactericidal in rapidly dividing bacteria, but bacteriostatic 
in slow dividing bacteria. INH was thought to be a highly effective drug at the beginning; however, 
RIF took over the property in bactericidal activity while PZA acting as sterilizing drug. PZA plays 
a role to kill semi-dormant TB bacilli which are hard to kill by other drugs (23, 24). Adding PZA 
to INH and RIF regimen could shorten the duration of TB treatment from 9 to 6 months (25, 26). 
 
Between 1994 and 2009, INH resistance was detected in 44.9% of all strains causing active 
tuberculosis in the Eastern European region, but 13.9% in all other regions (27). In 2014, the global 
frequency of non-MDR INH resistance was 9.5 %, 8.1% of new cases and 14.0% of retreatment 
case (28). According to the report from the global project on anti-TB drug resistance surveillance 
2002-07, MDR-TB contributed 4.8% to all estimated incident TB cases. This proportion of INH 
resistance and MDR in global report suggest that a major of INH resistance were INH mono and 
poly-resistance, not MDR (INH with concurrent RIF resistance) (29).  
 
The US National TB Surveillance System (NTSS) reported that PZA mono-resistant incidence 
among M. tb complex cases is 2.0-3.3% and is assumed to increase over time (30). Furthermore, 
the PZA resistance is harbored in 38% of MDR (31). PZA resistance testing is difficult to perform 
by growth-based testing because the PZA is active only in an acidic microenvironment (pH 5.5). 
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If inoculum is too heavy, the pH may be increased and drug activity will decrease (false resistance). 
In contrast, if inoculum is too light, pH may go down and M. tb will not grow well (false 
susceptibility) (32, 33). Because of this technical difficulty, most of mycobacteriology laboratories 
in the U.S. and other countries do not test for PZA. We lack prevalence of PZA resistance in global 
level from this problem. However, PZA phenotypic assay was done in LAC.   
 
The culture result only reported Mycobacterium Tuberculosis Complex (MTBC), which includes 
Mycobacterium tuberculosis, Mycobacterium africanum (subtypes I and II), Mycobacterium bovis 
(along with the attenuated M. bovis bacillus Calmette-Guérin [BCG]), and Mycobacterium microti 
(34). Mycobacterium bovis is intrinsically resistant to PZA and PZA mono-resistance is the unique 
characteristic of M. bovis (35, 36). M. bovis infects humans by unpasteurized dairy product 
ingestion and mostly manifest by extra pulmonary involvement (37, 38). Normally, M. bovis 
contributes a small proportion of TB cases in humans; on the other hand, M. bovis itself plays an 
important role in global wild and domestic animals (38). The way to differentiate M. tb from M. 
bovis from MTBC is using spacer oligonucleotide typing (spoligotyping) and mycobacterial 
interspersed repetitive unit variable number tandem repeats (MIRU-VNTR) techniques (37, 39). 
In this study, we focused on PZA mono-resistance in M. tb not M. bovis. 
 
In the light of variables selected in a multivariable analysis, previous studies have controlled for 
different potential confounders. However, many of the potential confounders identified may not 
significantly related to specific drug resistance patterns. Most researchers decide to include them 
in the final model (e.g. age, gender, race/ethnicity, U.S. born, and pulmonary/extra pulmonary 
status). With increasing age, male gender, race/ethnicity, nativity (U.S.-born vs. foreign born), and 
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site of disease were independently associated with mortality (40-42). INH mono-resistance was 
associated with only prior treatment for latent or active tuberculosis (18). PZA mono-resistance 
MTBC was associated with age, Hispanic race, and extra pulmonary disease (30), but a study in 
Quebec revealed that there was no significant association in mean age, gender, site of TB 
involvement between PZA mono-resistance and pan-susceptible (20). Although the association 
between these factors (age, gender, race, nativity, site of disease) and drug resistance pattern are 
inconclusive, we included these factors in our final model to adjust for baseline demographic as 
shown in figure 1.  
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CHAPTER III: METHODS 
 
Overall study design 
 
To evaluate the association of drug resistant patterns on the outcome of mortality, a retrospective 
cohort study testing the odds ratios of mortality among TB patients was conducted.  
 
Primary data source 
 
Data were extracted from the Tuberculosis Registry Information Management System (TRIMS) 
database. TRIMS database is maintained by the LAC DPH TB Control Program (TBCP). 
California Code of Regulation Title 17 Section 2500 which states that all cases of suspected TB 
have to be reported by health care provider in LAC within one working day. California Health and 
Safety Code Section 121362 also requires TBCP update and maintain a record of clinical follow 
up of all TB patients. TRIMS is the repository of all baseline and follow up information. TRIMS 
comprises many tables of patient demographics, disease characteristics, outcomes, inpatient 
admission and discharge dates, plan of treatment and case management and investigate close 
contacts. Since 2007, TRIMS has added genotyping information for culture-confirmed cases 
genotyped by CDC.  
 
Study population 
 
TB cases included in the final analysis had to meet these inclusion criteria: (1) 15 years or older; 
(2) newly diagnosed TB disease in TRIMS database; (3) culture confirmation; (4) completed DST 
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results; (5) completed genotypic results. All TB cases were reported to Los Angeles Tuberculosis 
Control Program and managed under the LAC jurisdiction between the January 1, 2010 and 
December 31, 2014. The date used to specify the period of study was the date when the patient 
was confirmed as TB case. TB cases in this study included patients with isolation of 
Mycobacterium tuberculosis complex from a clinical specimen.  New cases are defined as patients 
with tuberculosis who have never been treated with anti TB drugs or have received them for less 
than 1 month. 
 
In order to assess the M. TB with PZA mono-resistance on all-cause mortality in TB patients 
validly, we have to eliminate M. bovis infection from our analysis. We differentiate M. TB and M. 
bovis for a sub-set of MTBC by using spacer oligonucleotide typing (spoligotyping) and 
mycobacterial interspersed repetitive unit variable number tandem repeats (MIRU-VNTR) 
techniques. (37, 39, 43, 44). 
 
All TB cases from 2010-2014 who were alive at the time of diagnosis and have a start date for 
anti-TB therapy recorded were eligible (Figure 2). Patients were excluded if they had a TB case 
closure status of moved, lost to follow up, refused treatment, had adverse treatment event, pending, 
others, or missing (Figure 2).  
 
Primary exposure definition 
 
For the purpose of this analysis, the exposure of interest was the type of TB drug resistance pattern: 
all drug susceptible, INH mono-resistance, PZA mono-resistance, MDR-TB was also included in 
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the analysis, but we excluded the other resistance patterns. During 2010-2014, LAC public health 
laboratory used the MGIT 960 AST, Bactec 460 and agar proportion method on selected drugs. 
The critical concentration used in the standard test were >1% growth of M. tuberculosis complex 
in the concentration of INH at 0.2 µg/ml or 1 µg/ml on agar proportion method. PZA susceptibility 
testing was operated by using liquid culture in the Bactec460 or MGIT 960 system at a PZA 
concentration of 100 µg /ml. The Clinical and Laboratory Standard Institute suggested the 
BACTEC 460TB (BD, Sparks, MD, USA) as a reference method for PZA susceptibility (45).  
When production for reagent for BACTEC 460TB was stopped in 2011, BACTEC Mycobacterial 
Growth Indicator Tube (MGIT) 960 system (BD, Sparks, MD, USA) was used for PZA drug 
susceptibility testing in LAC public health laboratory. For the turnaround time, Bactec 460 and 
MGIT 960 (Commercial Broth System) take 12-14 days from the date drug susceptibility test was 
started, and 7H10 agar (Agar Proportion Method) takes 3 weeks from the date drug susceptibility 
test was started.    
 
Primary outcome definition 
 
The primary outcome of interest was all-cause mortality death among all TB cases. The definition 
of death rely on CDC, which counts any death that happens from the time of diagnosis to the time 
of treatment completion (46). Because the TBCP surveillance database provided only TB-related 
and non TB-related, the specific cause of death was not available for analysis. 
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Description of variables  
 
Specific fields were extracted from the TRIMS database to assess patient demographics (e.g. age, 
gender, race/ethnicity, US. vs. foreign born), clinical characteristics (pulmonary vs. extra 
pulmonary), underlying disease status (HIV infection, Diabetes Mellitus, kidney disease), and 
behavioral factors (excess alcohol use). (See Appendix, Table 4). Age is continuous variable, and 
others are categorical variables: (1) dichotomous variables (yes vs. no)-gender, diabetes mellitus, 
kidney disease; (2) nominal variables- race/ethnicity, US. born, excessive alcohol use, HIV status, 
disease characteristics, anti-TB drug resistance at baseline. 
 
Ethics Statement 
 
All data analyzed in this study came from the Los Angeles County Department of Public Health 
Tuberculosis Control Program as a part of surveillance data for public health scheme. 
 
Statistical Analysis 
 
All analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, North Carolina). 
Descriptive statistics were used to explain patient demographics, disease characteristics, excess 
alcohol use, diabetes mellitus, and status of HIV infection for the overall cohort. Continuous 
variables were reported by mean/median. Categorical variables were reported by the frequency 
and percentage. Age as a continuous variable was categorized at purposeful cut-points depended 
on the surveillance reports and previous studies.  
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We investigated factors associated with all-cause mortality during anti-TB treatment by estimating 
odds ratios (ORs) and 95% confidence intervals (95%CIs) in bivariate analyses. We chose 
predictors that were known as potential confounders of drug resistance and death from any cause 
during anti-TB treatment (e.g., age, gender, race, U.S. vs. foreign born, disease characteristic) by 
first constructing a directed acyclic graph (DAG) in figure 1. Predictors were included in the 
multiple logistic model if the predictor was associate with the exposure and outcome variables, but 
this inclusion did not rely on a pre-specified significant value. We also used the Hosmer-
Lemeshow test to assess model fit (47).   
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CHAPTER IV: RESULTS 
 
Overall, there were 2,201 (68.2%) cultured confirmed cases of M. tb reported to Los Angeles 
County Tuberculosis Control Program between January1, 2010 and December 31, 2014 (Figure 
2). Of these, 119 cases (3.7%) stopped TB treatment for reasons other than completion and death 
that were identified as: (1) adverse treatment 2 cases; (2) Lost to follow up 26 cases; (3) Move 39 
cases; (4) Other 40 cases; (5) Pending 1 case; (6) refused 4 cases; (7) missing 7 cases were excluded 
from the analysis because the treatment outcomes were unknown. Forty-four cases (1.4%) died 
before and at time of notification of TB diagnosis, leaving 2,038 cases alive and active TB cases 
at diagnosis. Among those alive at time of TB diagnosis, we also excluded 21 cases (1.0%) who 
died before receiving treatment, 25 cases (1.2%) who are younger than 15 years old and no death 
in this age category, and 63 cases (3.1%) who were relapse/reinfection of TB leaving only newly 
confirmed M. tb cases for analysis.  
 
Of 2,201 cases, 1,932 cases (88%) from the years 2010-2014 met final inclusion criteria for the 
retrospective cohort study (Figure 2). The majority of cases were male (63.6%) and the median 
age was 54 years old. (Table 1). One third of participants were in age group of 45-64 years old. 
Asian ethnicity accounted for 44.3% of cases and Hispanic ethnicity accounted for 41.5% of cases. 
At the time of diagnosis, 82.7 % of 1,932 cases were born outside U.S., 11.4 % reported using 
excess alcohol, 28.8% had Diabetes Mellitus, and 4.7% were HIV positive. For the disease 
characteristic of all TB cases, 63.7% were determined to be pulmonary without cavitation. 
 
Of 1,929 cases, there were 1,701 cases (88%) in the drug-susceptible group and 228 cases (12%) 
in the drug-resistant group. In the drug resistant group, a majority of drug resistant cases were INH 
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mono-resistance (n=149/228, 65%). Also, there were 29 cases (13%) in MDR-TB group and 28 
cases (12%) in PZA mono-resistance. The mortality rate in the drug susceptible group was 10.3% 
and the mortality rate in the drug resistant group was 14.5% (14%, 3.4%, and 25% in INH mono-
resistance, MDR, PZA mono-resistance, respectively) (table1). 
 
We found a higher death rate of INH mono-resistance and PZA mono-resistance when compared 
to drug susceptible cases (14.1% vs. 25% vs. 10.3%) (Table2). INH mono-resistance and PZA 
mono-resistance were more likely to occur in older age group than drug-susceptible (median age 
58 vs. 60.5 vs. 54 years), more likely to be foreign-born (90.6% vs. 89.3% vs. 81.8%) especially 
from Asia, and had a higher proportion of diabetes cases when compared with all drug susceptible 
patients (32.2% vs. 39.3% vs. 28.4%).  
 
For INH mono-resistance, other risk factors were quite similar to the drug-susceptible group, 
including male gender (63.8% vs 63.9%), known positive HIV infection (4.7% vs. 4.6%) and 
excess alcohol use (10.1% vs. 11.7%) (table2). For PZA mono-resistance, known positive HIV 
infection also mostly found in PZA mono-resistant group (10.7% vs. 4.6%). Moreover, one fourth 
of PZA mono-resistant cases were extra pulmonary (25% vs. 13.4%). In contrast, there was no 
excess alcohol use in this group.  
 
Trend of INH mono-resistant proportion from total TB cases increased from 2012 to 2014 (6.1% 
to 9.8%), corresponding to the increasing in Asian race/ethnicity proportion in TB patients in LAC 
(39.9% to 47.6%). At the same time, the trend of PZA mono-resistant proportion from total TB 
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cases was rising from 2010 to 2011 (0.3% to 2.1%) then distributed evenly from 2011 to 2013 
(2.1% and 1.9%) and slightly decreased to 1% in 2014 (figure3). 
 
Among the 207 who died during TB treatment, 79 (38.2%) died within 30 days of treatment, 41 
(19.8%) died between 30 and 60 days of treatment. More than half of deaths occurred within first 
two months or intensive of TB treatment (Figure 4). The median age was 73 years for all deaths. 
In 21 cases who died in INH mono-resistant group, almost half of cases (47.6%) died within two 
months of treatment; however, a majority of PZA mono-resistant (71.4%) died within two months 
of treatment.   
  
Patients with INH mono-resistance had an unadjusted odds of all-cause mortality during TB 
treatment that was 1.4 times the odds of mortality when compared to patients having drug-
susceptible (crude odds ratio [cOR] 1.43, 95% CI 0.88-2.33). After adjusting for potential 
confounding covariates (i.e. age, race, gender, U.S. vs. foreign born, extra pulmonary) using 
background knowledge and directed acyclic graph theory (see: Figure 1), the adjusted odds of all-
cause mortality for INH mono-resistant was found to be 1.57 times the odds of all-cause mortality 
for all drug-susceptible with a confidence interval span from 0.93 to 2.64 and including one 
(adjusted odds ratio [aOR] 1.57, 95% CI 0.93-2.64).  
 
In addition, patients with PZA mono-resistant had an unadjusted odds of all-cause mortality during 
TB treatment that was 2.91 times the odds of mortality when compared to patients having drug-
susceptible (crude odds ratio [cOR] 2.91, 95% CI 1.22-6.94). After adjusting for potentially 
confounding covariates, the magnitude of association and the significance of odds ratio was 
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reduced. The adjusted odds of all-cause mortality for PZA mono-resistant decreased to 2.43 times 
the odds of all-cause mortality for all drug-susceptible with a confidence interval span from 0.92 
to 6.44 and including one (adjusted odds ratio [aOR] 2.43, 95% CI 0.92-6.44).  
 
After adjusting for confounding factors, the results of multiple logistic regression showed that INH 
and PZA mono-resistance may increase the mortality, while PZA mono-resistance had wider 
confidence interval than INH mono-resistance. Older age, male gender, and pulmonary 
involvement might increase TB mortality, although some of the confidence intervals included one 
(table3).   
 
  
18 
CHAPTER V: DISCUSSION 
 
We identified the two major types of drug resistant TB and their associations with all-cause 
mortality during treatment. These results provide some understanding of drug resistance pattern in 
a low TB prevalence setting. The first pattern was INH mono-resistance that showed a moderate 
association with all-cause mortality. Secondly, PZA mono-resistant had a stronger association with 
all-cause mortality in this study samples.  
 
INH mono-resistance 
 
We found a high case fatality rate of 14% for 149 INH mono-resistant new TB patients. The 
percentage of total deaths had been documented as 10% of drug susceptible TB patients, including 
deaths due to TB and deaths unrelated to TB disease in LAC from 2010 to 2014. Our multiple 
logistic regression showed moderate association between INH resistance and all-cause TB 
mortality with a wide confidence interval consistent with many studies reporting that isoniazid 
resistance has been found to be a risk factor of unfavorable treatment outcome (i.e. loss to follow 
up, failure, transfer out, switch to MDR treatment) (7-9, 11-16, 48, 49). The relative small OR 
(1.5) comparing to OR 1.81 from van der Heijden’s study in South Africa (7) and Hazard ratio 3.3 
from Baez-Saldana study in Mexico (10) might be related to the differences in inclusion criteria, 
the treatment regimens used after knowing Drug susceptibility result, and a better TB program in 
LAC.  
 
The difference in inclusion criteria for our study came from the strict criteria that included only 
primary INH resistance and newly confirm TB cases in our study and Cattamanchi’s study (18). 
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Including these cases would select a healthier group of participant based on the result from 
Aibana’s and Choi’s study that showed patients with a previous TB history tended to have poor 
treatment outcome (50, 51). On the other hand, the rest of the studies which included both new 
and retreatment cases may have a biased study results (outcome worse than it should be). Although 
previous researchers adjusted for history of TB treatment, there is some residual bias from too 
broad category of previous TB treatment such as the episode of diagnosed TB disease: the second 
episode would not same as the fifth episode in the aspect of organ damage. In short, the previous 
studies which include retreatment cases may not have provided an accurate estimate of the 
association between INH mono-resistance and TB mortality.  
 
The regimen adapted after knowing DST (Drug Susceptibility Test) result could have impacted 
the treatment outcome. In our study, the treatment would change to Rifampicin, Pyrazinamide, and 
Ethambutol upon confirmation of DST result for six to nine months or Rifampicin and Ethambutol 
and Fluoroquinolone for 9 to 12 months (if PZA toxicity becomes an issue) after INH mono-
resistant result reported according to standard practice of physician in LAC at that time. This 
Rifampicin, Pyrazinamide, and Ethambutol regimen showing 95 to 98 percent success rate among 
107 patients with INH mono-resistant TB (52), It is also supported by retrospective studies of 
Cattamanchi and Bang that adjusted regimen based on the result of drug susceptibility test. Both 
studies reported that there was no effect of INH mono-resistance on TB treatment outcome of 
standard modified treatment.  
 
Nonetheless, the studies reporting poor treatment outcome reported using the WHO standard 
schedule of initiating therapy with 4 drugs (2HRZE/4HR) for newly diagnosed patients and 5 drugs 
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(2HREZES/1HRZE/5HRE) for previously treated patients and most of the program did not adjust 
for INH mono-resistance. Fluoroquinolones were not included in treatment schedules for these 
patients. The wide range of odds ratio based on wide CI in this study might came from the timing 
when health care providers tailoring regimen based on DST result. If they know DST early and 
change treatment regimen immediately, you might not see the difference between INH mono-
resistance and the drug susceptible group. In contrast, if they don’t know DST result or patients 
may have died prior to DST results being known, the treatment outcome in INH mono-resistance 
might be worse from continuing unadjusted regimen. 
 
In this study, TB treatment was given by directly observed therapy (DOT) from health providers 
after knowing INH mono-resistant status according to standard practice in LAC. DOT by health 
providers is also supported by study of public health supervision effect on mortality with 
tuberculosis in Los Angeles County, 2010-2014. This study revealed that patients without any 
supervision from health department experienced approximately double the risk of death as those 
patients with supervision form health department (53). The results from this DOT study supported 
our result which was lower than expected between INH mono-resistance and mortality after 
receiving DOT by healthcare provider, it could be due to the use of DOT improved outcomes in 
some patients. However, most studies did not mention about treatment adherence or DOT status. 
In our study, we also did not adjust for type of supervision because it is not a confounding factor 
in our model.   
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PZA mono-resistance 
 
We found a higher death rate of PZA mono-resistance when compared to drug susceptible cases 
or INH mono-resistance (25% vs. 10.3% vs.14.1%). In spite of the width of confidence interval, 
PZA mono-resistance might indicate the strong association by the high value of OR (2.43). It’s 
could be explained by the fact that almost three fourth of PZA mono-resistant cases died within 
two months, so these early deaths occurred before the DST results were available. This result 
supported by the Yee’s study from Quebec after excluding M. bovis. They also reported the worse 
clinical outcome of PZA mono-resistance compare to all drug susceptible (20). On the other hand, 
the result from Budzik from San Francisco did not find any significant association between PZA 
resistance and treatment failure (p=0.51) (21). However, Budzik’s study included M. bovis, while 
our study focused on M. tb. Also, patients with M. bovis tended to have better treatment outcome 
compare to M. tb, which may explain the different result from Budzik’s study to our study.  
 
The strong association of PZA mono-resistant cases with less precision of statistical estimation 
and including null value may be due to the few number of cases after excluding M. bovis from 
PZA mono-resistance. Secondly, the misclassification from inaccurate PZA resistance that could 
happen from either false resistance (pH rising in heavy inoculum and the decrease in PZA activity) 
or false susceptibility (M. tb could not grow well in low pH from too light inoculum) that can 
create bias towards the null.  
 
In PZA resistant cases from our study, about 56% were due to M. bovis (79/141). After excluding 
M. bovis, PZA resistance was identified only 2.6% (50 of 1929) of mycobacterial isolate tested 
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from new TB cases in LAC which was consistent with the report from national surveillance data 
(30). After excluding MDR-PZA (13 of 50) and any PZA resistance more than one drug, we had 
only 28 cases of PZA mono-resistance left (1.5%). This problem of small sample size might affect 
the power of the study, and be reflected wide confidence interval.  
 
The difficulty in testing for PZA resistance originated by using MGIT 960 system for PZA drug 
susceptibility testing (DST). This system might create some potential for false-resistance test 
results for PZA (33, 54). According to of non- differential misclassification of PZA resistant status 
on our dichotomous outcome as complete and died, we could predict that our odds ratios presented 
can be biased toward the null base on the assumption that PZA resistant would not affect 
misclassification of the closure status, and the closure status would not affect the misclassification 
of PZA resistance, too.  
 
Multidrug-resistant  
 
MDR showed less precision of odds ratios for all-cause mortality ranging from 0.09 to 5.23. This 
conflicted with most of the previous studies that reported success rate for MDR-TB range from 30 
to 80 percent (55-59). We can explain these unexpected outcomes by three factors. The first there 
were few cases of MDR-TB in LAC and only one death, thus we did not have enough effect size 
to estimate the magnitude of the association. The second factor might due to the strong TB program 
in LAC.  
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Given such a positive finding from MDR-TB treatment in LAC, the few number of deaths might 
come from the strong TB control program in LAC which dedicate all resource to treat MDR-TB 
patients. We can speculate that if INH mono-resistance and PZA mono-resistance receive the same 
level of treatment and care as MDR-TB, the TB mortality rate in INH and PZA mono-resistance 
would reduce dramatically and prevent the development from mono-resistance to poly-resistance 
or MDR-TB in the future.   
 
Limitation 
 
A potential limitation is the patient cohort for analysis was restricted to patients with a known case 
closure status, only completion of treatment and death. Those patients who had adverse treatment 
event, moved, lost to follow-up, pending case closure or refused treatment were excluded; patients 
who lost to follow up or refuse treatment can cause some bias to our study if they had unique 
characteristic which relate to our study. In order to ascertain our treatment outcome, 119 cases had 
to be excluded from the study. (n=119/3226, 3.7%). However, four percent is a very low proportion 
and not likely to have an effect on the findings. 
 
In addition, we did not collect INH and PZA -resistance conferring mutation due to unavailability 
of pyrosequencing and Sanger sequencing in LAC public health laboratory. Given such an unclear 
result on katG and inhA on TB treatment outcomes, we could not draw inferences about which 
type of mutation are associated with worse treatment outcomes. Moreover, the techniques using 
for testing PZA in MGIT are subject to different interpretation of results, yielding either false 
resistance or false susceptibility. However, this misclassification would bias our result towards the 
null, so the effect of PZA mono-resistance might be even stronger.     
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Next, we cannot evaluate the efficacy of adapting regimen after INH and PZA DST result were 
reported because there is no data available from our surveillance system (TRIMS). Last, death with 
TB are not similar to death due to TB. Based on the CDC definition, all deaths that occur after a 
patient is diagnosed with TB and before they complete TB treatment is considered a TB death. As 
a result, this includes patients that may have died from TB-unrelated causes. Nonetheless, this 
study only included cases who died during TB treatment. 
 
Recommendation 
 
In this study, patients with INH or PZA mono-resistance were more likely to die than patients with 
drug-susceptible TB. Efforts are needed to improve treatment outcomes for INH or PZA mono-
resistant TB patients.  Recommendations for further studies include: (1) review of medical records 
to verify the actual cause of death and select only TB-related death and focus especially in INH 
and PZA mono-resistant cases due to high mortality in both groups; (2) investigation of the 
effectiveness of the regimens, time when starting adjusted treatment and dosage of anti-TB drug 
for the drug resistance groups; (3) identify the association of INH conferring mutation and 
treatment outcome; (4) explore the cause of an increasing trend in INH mono-resistance from 2012 
to 2014. 
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APPENDICES 
 
Figure 1. Drug Resistant Pattern and TB Mortality, Directed acyclic graph (DAG). 
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Figure 2. TB Cases Reported to Los Angeles County, 2010-2014. 
 
 
 
  
Confirmed TB Cases (laboratory and/or 
clinical diagnosis) from 2010-2014,          
Los Angeles County.  
N= 3,226 
By exclusion criteria (1,188)  
649 cases who did not have genotypic result  
243 cases who were duplicated  
84 cases whose genotype result was shown M. Bovis 
49 cases whose genotype and drug susceptibility 
result were missing   
119 cases stopped treatment for reason other than 
completion or death 
44 cases died before or at notification of TB:  
Alive Active TB cases at diagnosis, n=2,038  
Drug-susceptible  
n=1,701 
Death rate 
176/1,701=10.3% 
Drug-resistance 
n=228 
=29 
Exclude from analysis (109)  
Dead before or at starting treatment: 21 
Age less than 15 years old: 25          
Relapse/Reinfection with TB: 63  
             
Death rate 
33/228=14.5% 
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Figure 3. Number of TB cases with MDR, INH mono-resistant, PZA mono-resistant, and 
other resistant among TB Cases Reported to Los Angeles County, 2010-2014. (n=228)  
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Figure 4. Time from tuberculosis treatment start to death, among patients who died, 
California, 2010-2014 (n=207).  
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Table 1. Characteristics of TB cases by treatment outcome status, Los Angeles County 
2010-2014. (n=1,929) 
 
    Treatment Outcome 
Overall1 Complete Died 
N (%) N (%) N (%) 
Total 1929 (100.0%) 1722 (100.0%) 207 (100.0%) 
Male 1226 (63.6%) 1080 (62.7%) 146 (70.5%) 
Age (years)             
15-34 years 369 (19.1%) 362 (21.0%) 7 (3.4%) 
35-44 years 253 (13.1%) 245 (14.2%) 8 (3.9%) 
45-54 years 343 (17.8%) 318 (18.5%) 25 (12.1%) 
55-64 years 346 (17.9%) 315 (18.3%) 31 (15.0%) 
65-74 years 263 (13.6%) 224 (13.0%) 39 (18.8%) 
75-84 years 203 (10.5%) 173 (10.0%) 30 (14.5%) 
85+ years 152 (7.9%) 85 (4.9%) 67 (32.4%) 
Race/Ethnicity 
103 (5.3%) 87 (5.1%) 16 (7.7%) Non-Hispanic White 
Hispanic 800 (41.5%) 730 (42.4%) 70 (33.8%) 
African American 172 (8.9%) 158 (9.2%) 14 (6.8%) 
Asian 854 (44.3%) 747 (43.4%) 107 (51.7%) 
U.S. Born 331 (17.2%) 299 (17.4%) 32 (15.5%) 
Excessive Alcohol Use 220 (11.4%) 202 (11.7%) 18 (8.7%) 
Diabetes Mellitus 556 (28.8%) 467 (27.1%) 89 (43.0%) 
HIV Status             
Known Positive 91 (4.7%) 83 (4.8%) 8 (3.9%) 
Known Negative 1732 (89.8%) 1577 (91.6%) 155 (74.9%) 
Not done/Unknown result 70 (3.6%) 32 (1.9%) 38 (18.4%) 
Refused 36 (1.9%) 30 (1.7%) 6 (2.9%) 
Disease characteristics: 
site, cavitation 
            
Pulmonary and cavitary 445 (23.1%) 419 (24.3%) 26 (12.6%) 
Pulmonary, not cavitary 1229 (63.7%) 1067 (62.0%) 162 (78.3%) 
Extra pulmonary  255 (13.2%) 236 (13.7%) 19 (9.2%) 
ANTI-TB DRUG RESISTANCE 
AT BASELINE             
        All susceptible  1701 (88.2%) 1526 (88.6%) 175 (84.5%) 
        INH Mono-resistant 149 (7.7%) 128 (7.4%) 21 (10.1%) 
        RIF Mono-resistant 4 (0.2%) 4 (0.2%) 0 (0.0%) 
        PZA Mono-resistant 28 (1.5%) 21 (1.2%) 7 (3.4%) 
        Multi-drug resistant 29 (1.5%) 28 (1.6%) 1 (0.5%) 
        Other  18 (0.9%) 15 (0.9%) 3 (1.5%) 
1 Percentages may not sum to 100% due to missing data. 
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Table 2. Characteristics of TB cases by drug resistant pattern, Los Angeles County 2010-
2014. (n=1,929) 
 
 Drug resistant pattern 
 All susceptible INH mono-resistant PZA mono-resistant  
 N (%) N (%) N (%)  
Total 1701 (100.0%) 149 (100.0%) 28 (100.0%) 
    Male   1087 (63.9%) 95 (63.8%) 15 (53.6%) 
Age, median 54 years 58 years 60.5 years 
Age (years)       
    15-34 330 (19.4%) 21 (14.1%) 1 (3.6%) 
    35-44 218 (12.8%) 21 (14.1%) 4 (14.3%) 
    45-54 303 (17.8%) 25 (16.8%) 4 (14.3%) 
    55-64 306 (18%) 28 (18.8%) 7 (25%) 
    65-74 231 (13.6%) 25 (16.8%) 3 (10.7%) 
    75-84 175 (10.3%) 22 (14.8%) 4 (14.3%) 
    85+   138 (8.1%) 7 (4.7%) 5 (17.9%) 
Race/Ethnicity       
    Non-Hispanic 
White 92 (5.4%) 5 (3.4%) 4 (14.3%) 
    Hispanic           731 (43%) 49 (32.9%) 6 (21.4%) 
    African American   164 (9.6%) 8 (5.4%) 0 (0%) 
    Asian              714 (42%) 87 (58.4%) 18 (64.3%) 
US-born 310 (18.2%) 14 (9.4%) 3 (10.7%) 
Excess alcohol 199 (11.7%) 15 (10.1%) 0 (0%) 
Diabetes mellitus 483 (28.4%) 48 (32.2%) 11 (39.3%) 
HIV status       
    Known Positive 78 (4.6%) 7 (4.7%) 3 (10.7%) 
    Known Negative 1528 (89.8%) 133 (89.3%) 24 (85.7%) 
    Not done/Unknown 
result  61 (3.6%) 7 (4.7%) 1 (3.6%) 
    Refused  34 (2%) 2 (1.3%) 0 (0%) 
Extra pulmonary 228 (13.4%) 16 (10.7%) 7 (25%) 
Outcome       
    Complete 1526 (89.7%) 128 (85.9%) 21 (75%) 
    Died     175 (10.3%) 21 (14.1%) 7 (25%) 
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Table 3. Crude and Adjusted odds ratio of risk of all-cause mortality among Bacteriological 
confirmed TB patients, LAC, 2010-2014 (n=1,927*) 
 
 Crude odds ratio (cOR) Adjusted odds ratio (aOR) 
cOR 95% CI aOR 95% CI 
Gender     
  Female  1.00 --- 1.00 --- 
  Male 1.42 1.04, 1.95 1.32 0.94, 1.86 
Age Group     
  15-34 1.00 --- 1.00 --- 
  35-44 1.69 0.60, 4.71 1.69 0.60, 4.74 
  45-54 4.06 1.73, 9.52 3.93 1.66, 9.29 
  55-64 5.09 2.21, 11.71 5.09 2.18, 11.86 
  65-74 9.00 3.96, 20.46 9.09 3.94, 20.94 
  75-84 8.96 3.86, 20.81 8.94 3.80, 21.02 
  85+  40.74 18.06, 91.90 40.57 17.64, 93.31 
Race/Ethnicity     
  Hispanic 1.00 --- 1.00 --- 
  Non-Hispanic White 1.92 1.07, 3.45 0.98 0.49, 1.95 
  Asian 1.49 1.09, 2.05 0.97 0.68, 1.39 
  African American 0.92 0.51, 1.68 0.83 0.39, 1.76 
U.S. Born     
  No 1.00 --- 1.00 --- 
  Yes  0.87 0.58, 1.29 1.25 0.71, 2.21 
Pulmonary     
  No 1.00 ---  1.00 --- 
  Yes 1.57 0.96, 2.57 1.52 0.90, 2.56 
Drug susceptibility test 
pattern 
    
  All susceptible  1.00 --- 1.00 --- 
  Multi-drug resistant  0.31 0.04, 2.30 0.68 0.09, 5.23 
  INH Mono-resistant 1.43 0.88, 2.33 1.57 0.93, 2.64 
  PZA Mono-resistant 2.91 1.22, 6.94 2.43 0.92, 6.44 
  Other 1.37 0.40, 4.70 1.68 0.43, 6.51 
 
Hosmer and Lemeshow Goodness-of-fit Test: P Value = 0.80 
*2 observations were deleted due to missing values for the response or explanatory variables.  
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Table 4. Description of covariates abstracted from TRIMS database. 
 
Variable Type Description Additional notes 
Age Continuous At time of diagnosis  
Sex Categorical: 
Male, Female, no 
data 
At time of diagnosis 
 
 
Race/ethnicity Categorical: 
Non-Hispanic 
White, Hispanic, 
Asian, African 
American. 
 Due to small sample size, 
Native Hawaiian/Alaska 
Native was collapsed 
within the Asian category. 
US Born 
 
Categorical: Yes, 
No, Unknown. 
Was the patient born 
in the United States 
 
Excessive Alcohol  Categorical: Yes, 
No, Unknown 
 
Within the last year, 
at time of diagnosis. 
Patient self-report. 
 
Diabetes Mellitus Dichotomous: 
Yes, No 
Patient has a 
diagnosis of diabetes 
mellitus (I or II) 
either before or at the 
time of TB 
diagnosis. 
Diabetes may either be 
controlled by diet or 
medication. 
HIV Status Categorical: 
Negative, No 
Data, Not Done, 
Positive, 
Refused,  
The HIV status of 
the patient 
 
Site of TB Disease 
 
Categorical: 
Pulmonary, 
extra-pulmonary. 
 Pulmonary is defined 
strictly as pulmonary only, 
excluding pleural and 
laryngeal. 
Cavitary disease 
 
Dichotomous: 
Yes, No 
 
Any initial chest 
radiograph showing 
abnormalities 
consistent with TB 
and marked as 
cavitary. 
Based on results of initial 
CXR only. Does not 
include CT results. 
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Variable Type Description Additional notes 
Anti-TB drug 
resistance 
Categorical:  
All susceptible, 
INH mono-
resistance,  
PZA mono-
resistance,  
RIF mono-
resistance,  
Multi-drug 
resistant TB, 
Other resistance.  
Resistance variables 
based on DST results 
MDR: Defined by CDC; 
resistance to at least INH 
and RIF (CDC). Includes 
those who are MDR. 
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